Incyte (INCY) Tops Q4 EPS by 20c

Incyte (NASDAQ: INCY) reported Q4 EPS of $0.29, $0.20 better than the analyst estimate of $0.09. Revenue for the quarter came in at $243.9 million versus the consensus estimate of $225.92 million.

2016 guidance for Jakafi net product revenues in the range of $800 million to $815 million, reflecting expectations for continued growth in underlying demand in myelofibrosis (MF) and an increasing contribution from the ongoing launch in polycythemia vera (PV)

For earnings history and earnings-related data on Incyte (INCY) click here.

You May Also Be Interested In

• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
• AutoZone beats profit view but misses on revenue
• Incyte to present skin disease data at EADV congress in Vienna